Healthy pregnancy hub

Citalopram (Celexa®) | Escitalopram (Cipralex®)

Last Update: 09 Apr 2025

Welcome to our fact sheet on citalopram (Celexa®) and escitalopram (Cipralex®) during pregnancy and breastfeeding/ chestfeeding. This information should not take the place of medical care and advice from your healthcare provider.

The HEALTHY PREGNANCY HUB team is collaborating with MotherToBaby to share information on this topic. The original version is available here (updated on January 2023). 

Serene, our chatbot, can also answer your questions about medications during pregnancy. 

Please note that this fact sheet is based on United States information and has been adapted for Canada, with a review by our Canadian experts. Minor differences may exist between the two countries. Always consult your healthcare professional for information tailored to your situation. 

1. What is citalopram and escitalopram?

Citalopram is a medication that has been used to treat depression. Citalopram belongs to the class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). A common brand name for citalopram is Celexa®. 

Escitalopram contains the same active medication as citalopram. These two drugs act in the body in a very similar way. Escitalopram has been used to treat depression and generalized anxiety disorder. It also belongs to the class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). A common brand name is Lexapro® in the United States or Cipralex® in Canada. 

MotherToBaby has a fact sheet on depression here, and a factsheet on anxiety is available here. 

Sometimes when people find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take your medication. Your healthcare providers can talk with you about the benefits of treating your condition and the risks of untreated illness during pregnancy. 

Some people may have a return of their symptoms (relapse) if they stop this medication during pregnancy. Stopping this medication suddenly can cause some people to have withdrawal symptoms. If you plan to stop this medication, your healthcare provider may suggest that you slowly lower the dose instead of stopping all at once. Also, should you choose to stop taking this medication, it is important to have other forms of support in place (e.g. counselling or therapy) and a plan to restart the medication after delivery, if needed. 

2. What are the risks according to research?

I take citalopram or escitalopram. Can it make it harder for me to get pregnant?

It is not known if citalopram or escitalopram can make it harder for a person to get pregnant. Studies in animals found that citalopram might cause some reduced fertility (ability to get pregnant). 

Does taking citalopram or escitalopram increase the chance of miscarriage?

Miscarriage is common and can occur in any pregnancy for many different reasons. There have been some studies that suggested taking antidepressant medications might slightly increase the chance of miscarriage. However, a study on citalopram and escitalopram did not find an increased chance of miscarriage in individuals taking these medications. 

Does taking citalopram or escitalopram increase the chance of birth defects?

Every pregnancy starts out with a 3-5% chance of having a birth defect. This is called the background risk. There are reports of more than 15,000 pregnancies exposed to citalopram/escitalopram. Overall, the available data do not suggest that citalopram/escitalopram increases the chance of birth defects. While some reports have suggested an increased chance of heart defects or other birth defects, most studies have not found an increased chance of birth defects. 

Does taking citalopram or escitalopram in pregnancy increase the chance of other pregnancy-related problems?

Some studies suggest that taking citalopram/escitalopram throughout the pregnancy might increase the chance of pregnancy-related problems such as preterm birth (birth before 37 weeks of pregnancy) and low birth weight (weighing less than 5 pounds, 8 ounces [2500 grams] at birth). However, research has also shown that when depression is left untreated during pregnancy, there could be an increased chance of pregnancy complications. This makes it hard to know if it is the medication, untreated depression, or other factors that are increasing the chance for these problems. 

Some, but not all, studies have suggested that when pregnant individuals take SSRIs such as escitalopram or citalopram during the second half of the pregnancy, their babies might have an higher chance for a serious lung condition called persistent pulmonary hypertension. Persistent pulmonary hypertension happens in 1 or 2 out of 1,000 births. Among the studies looking at this, the overall chance for pulmonary hypertension when an SSRI was used in pregnancy was less than 1/100 (less than 1%). 

I need to take citalopram or escitalopram throughout my entire pregnancy. Will it cause withdrawal symptoms in my baby after birth?

Some medications taken during pregnancy are associated with withdrawal symptoms in a newborn after delivery. If you are taking escitalopram or citalopram at the time of delivery, your baby might have irritability, jitteriness, tremors (shivering), constant crying, different sleep patterns, problems with eating and controlling body temperature, and some problems with breathing. In most cases, these symptoms are mild and go away within a couple weeks with no treatment. Some babies may need to stay in the nursery or NICU until the symptoms go away. Most babies exposed to escitalopram or citalopram in late pregnancy do not have these symptoms. It is important that your healthcare providers know you are taking these medications so that if symptoms occur your baby can get the care that is best for them. 

Does taking citalopram or escitalopram in pregnancy affect future behavior or learning for the child?

One small study followed eleven babies exposed to citalopram during pregnancy. At one year of age there was no difference in their development compared to children who were not exposed to citalopram. Most studies find no increase in attention deficit hyperactivity disorder (ADHD) in children exposed to SSRIs during pregnancy. Most studies also find that SSRIs do not appear to increase the chance of autism spectrum disorder (ASD) after considering the effects of maternal depression or other factors. 

What screenings or tests are available to see if my pregnancy has birth defects or other issues?

Prenatal ultrasounds can be used to screen for some birth defects and to monitor the growth of the pregnancy. Talk with your healthcare provider about any prenatal screenings or testing that are available to you. 

3. Breastfeeding/ chestfeeding while taking citalopram or escitalopram

Several studies have shown that small amounts of citalopram/ escitalopram are found in breast milk/ human milk. There have been a few case reports of sleepiness and weight loss, but in most studies no harmful effects were seen in breastfed/ chestfed babies. Studies also showed no difference in the intellectual development of babies exposed to citalopram or escitalopram during breastfeeding/ chestfeeding. A nursing infant should be monitored for being very sleepy (hard to wake for feeds), poor feeding and poor weight gain, especially in younger, exclusively breastfed/ chestfed infants and when a combination of medications for mental health are used. Be sure to talk to your healthcare provider about all your breastfeeding/ chestfeeding questions. 

4. Fathers and sperm donors

If a male takes citalopram or escitalopram, could it affect his fertility or increase the chance of birth defects?

Escitalopram/ citalopram and other SSRIs have been reported to cause some sexual side effects in males, such as lower sexual desire or problems with ejaculation. There are several cases reports where sperm quality was affected with long-term escitalopram/ citalopram use. The sperm quality improved when the medication was stopped. In general, exposures that fathers or sperm donors have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures here

Key points

  • Citalopram and escitalopram are antidepressants used to treat depression and anxiety.
  • Available studies do not show that these medications increase the risk of birth defects, but some research suggests a slightly higher risk of preterm birth or low birth weight.
  • Some newborns exposed in late pregnancy may experience temporary symptoms after birth, such as irritability or sleep disturbances.
  • Small amounts pass into breast milk/ human milk, but most babies do not show any adverse effects.
  • Before stopping or changing your treatment, always talk to your healthcare team.

References

Please click here for references. 

 

*National Pregnancy Registry for Psychiatric Medications: There is a pregnancy registry for women who take psychiatric medications, such as citalopram and escitalopram. For more information you can look at their website: https://womensmentalhealth.org/research/pregnancyregistry/. 

URL copied!

Disclaimer

HEALTHY PREGNANCY HUB provides a source of information validated by health professionals; however, this information is provided for informational purposes only and should not replace professional advice. Medical standards and practices evolve as new data becomes available, so it is imperative to consult your doctor or a qualified health professional for any questions or concerns regarding your health without delay or omission. It is the responsibility of your treating physician or any other health professional, based on their independent experience and knowledge of the patient, to determine the best way to evaluate and treat you.

HEALTHY PREGNANCY HUB does not specifically recommend or endorse any test, practitioner, treatment, product, or opinion mentioned on our platform. HEALTHY PREGNANCY HUB also does not replace the individual patient assessment based on the examination by the healthcare provider of each patient and the consideration of laboratory data and other patient-specific factors.

The use of the information available on our site is at your own risk. No person involved in the creation, production, promotion, or marketing of HEALTHY PREGNANCY HUB guarantees or represents, expressly or implicitly, anything regarding the information available on the platform, which is provided “as it is”. All warranties are expressly excluded and disclaimed, including but not limited to implied warranties of merchantability or fitness for a particular purpose, as well as any warranties arising by law or otherwise in law or from trade or usage. Any statements or representations made by any other person or entity are void.

While consulting symptoms or other medical information on our platform may guide your discussions with your healthcare professional, this information should not be used to make a medical diagnosis or determine treatment. Before making changes to your supplement or medication regimen, please discuss with your medical team or contact 811 (Canada) to ensure the relevance of these changes to your individual situation.

Credits
MotherToBaby
Organization of Teratology Information Specialists (OTIS)
View source
Émy Roberge
Centre hospitalier universitaire Sainte-Justine
Brigitte Martin
Centre Hospitalier Universitaire Sainte-Justine

Associated Fact Sheets

Would you like to know more about this topic? Explore our associated Fact Sheets.

Associated Resources

In this section, you can browse, in one place, through our various documents and tools for pregnant people, their families and healthcare professionals. You'll find vidéos, downloadable brochures, podcast episodes, and more!

Partners

Your pregnancy during COVID-19
uOttawa
University of Calgary
University of British Columbia
University of Saskatchewan
University of Manitoba
University of Alberta
Unité de soutien SSA
UDEM
Stratos
SOGC
RQRM
QTNPR
QPC
PWHR
Public Health Agency of Canada
PregMed France
SPOR
MPrint
Mitacs
Médicaments Grossesse
McGill
Médicament Québec
FRQ
Perinatal Network
CIHR
IQVIA
iPOP
Institut national de santé publique du Québec
INRS
Innovative Medicines Canada
IN-uTERO
Immerscience
Groww
Enrich
Design Develop Discover
CUSM
CIHR
CHU Sainte-Justine
Centre of Excellence on Partnership with Patients and the Public
CAN-AIM
Canadian Pharmacogenomics Network for Drug Safetry
CAMCCO
CAMCCO-L
C4T
BORN Ontario
Black Physicians of Canada
BC Children's Hospital
Alberta Health Services
MICYRN
UQAT
Dalhousie University